The Clinical Significance of Detection of Serum Smac in Epithelial Ovarian Cancer

Abstract

Abstract: Objective：To investigate the clinical significance of serum Smac level in diagnosis and illness monitoring of epithelial ovarian carcinoma. Methods：The study collected 100 patients with ovary tumor who experienced the surgical treatment in Tianjin Central Hospital of Gynecology Obstetrics from December 2015 to January 2017. According to the pathological diagnosis of benign and malignant, all seclected patients were divided into benign ovarian tumor group (n=40) and epithelial ovarian cancer group (n=60). In addition to seclect the health control group (n=40) after medical examinationin in our hospital. Fasting serum were collected before and after surgery and chemotherapy. The level of serum Smac was detected by ELISA. Results：Serum Smac expression level in epithelial ovarian cancer was significantly lower than that of healthy controls and benign ovarian tumor group (P＜0.05). Accorrding to ROC curve, the critical value of serum Smac is determined to be 429.39 pmo/L. The Sensitivity of Smac single detection up to 91.67%, the specificity is 95%. The positive number of Smac in Ⅰ+Ⅱ phase was 14, the positive rate was 87.50%, the positive number of Smac in Ⅲ+Ⅳ phase was 41, the positive rate was 93.18%, the difference was not statistically significant (P＞0.05). Serum Smac was independent of age, pathological type, ascites, NLR and PLR, while it was associated with FIGO stage and lymph node metastasis. Smac expression level was higher than preoperative serum after the operation. The expression level of serum differences before and after the surgery were statistically significant (P=0.000), with the increase of number of chemotherapy, Smac level increased. Smac increased to normal at the end of the 2 period of chemotherapy. Conclusions：Serum Smac can be used to detect early ovarian cancer and may play an important role in differentiating benign and malignant ovarian tumors and monitoring the prognosis of postoperative ovarian cancer.

Key words: Mitochondrial membrane transport proteins, Ovarian neoplasms, Antineoplastic combined chemotherapy protocols, Second mitochondrical activator of caspase

XU Xin-ran，WANG Xin，ZHANG Hong，LIU Ming-yan，CHEN-Qi，CHEN Si-si. The Clinical Significance of Detection of Serum Smac in Epithelial Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2017, 44(6): 699-702.

References

参考文献 [1] Dinkelspiel H E, Champer M, Hou J, et al. Long-term mortality among women with epithelial ovarian cancer[J]. Gynecologic Oncology, 2015,138(2):421-428. [2] Latha TS, Panati K, Gowd DS,et al. Ovarian cancer biology and immunotherapy[J]. Int Rev Immunol. 2014,33(5):428-440. [3] Rong LW, Wang RX, Zheng XL，et al. Combination of wogonin and sorafenib effectively kills human hepatocellular carcinoma cells through apoptosis potentiation and autophagy inhibition[J]. Oncol Lett.,2017 ,13(6):5028-5034. [4] Du C, Fang M, Li Y, et al. Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition[J]. Cell, 2000,102(1):33-42. [5] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2016[J]. CA: A Cancer Journal for Clinicians, 2016,66(1):7-30. [6] Lim MC1, Yoo HJ, Song YJ，et al. Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer[J]. 2017 ,28(4):e48. [7] Harada T, Nakamura Y, Sato K, et al. Near-infrared photoimmunotherapy with galactosyl serum albumin in a model of diffuse peritoneal disseminated ovarian cancer[J]. Oncotarget, 2016,7(48):79408-79416. [8] Diab Y, Muallem MZ2. Targeted Therapy in Ovarian Cancer. A Comprehensive Systematic Review of Literature[J]. Anticancer Res. 2017 ,37(6):2809-2815. [9] Joerger AC, Fersht AR. The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches[J].Annu Rev Biochem,2016,2(85):375-404. [10] Gislefoss R E, Langseth H, Bolstad N, et al. HE4 as an Early Detection Biomarker of Epithelial Ovarian Cancer[J]. International Journal of Gynecological Cancer, 2015,25(9):1608-1615. [11] Kappelmayer J, Antal-Szalmás P, Nagy B. Human epididymis protein 4 (HE4) in laboratory medicine and an algorithm in renal disorders[J]. Clinica Chimica Acta, 2015,438:35-42. [12] Dobrzycka B, Mackowiak-Matejczyk B, Terlikowska K M, et al. Prognostic significance of pretreatment VEGF, survivin, and Smac/DIABLO serum levels in patients with serous ovarian carcinoma[J]. Tumor Biology, 2015,36(6):4157-4165. [13] 王鑫, 张虹. 术前NLR和PLR对上皮性卵巢癌患者预后的评估价值[J]. 现代妇产科进展, 2016(06):433-436. [14] Fulda S. Promises and Challenges of Smac Mimetics as Cancer Therapeutics[J]. Clinical Cancer Research, 2015,21(22):5030-5036.

[1]	BAI Yao-jun, WANG Si-yao, LING Fei-fei, ZHANG Sen-huai, LI Hong-li, LIU Chang. Progress of Trop-2 and Targeted Trop-2 Antibody-Coupled Drugs in Gynecological Malignant Tumors [J]. Journal of International Obstetrics and Gynecology, 2025, 52(1): 1-7.
[2]	ZHANG Yun-feng, ZHANG Wan-yue, LU Yue, WANG Yang-yang, JING Jia-yu, MU Jing-yi, WANG Yue. Research Progress of ARID1A and PIK3CA Mutations in Malignant Transformation of Ovarian Endometriosis [J]. Journal of International Obstetrics and Gynecology, 2025, 52(1): 19-22.
[3]	LI Nan, PENG Er-xuan, LIU Feng-hua. Clinical Analysis of 20 Cases of Brain Metastasis from Ovarian Epithelial Carcinoma [J]. Journal of International Obstetrics and Gynecology, 2025, 52(1): 23-27.
[4]	JIA Yan-feng, WU Zhen-zhen, WANG Wei-hong, WANG Yue-yuan, LI Juan. A Case of Primary Ovarian Adenosquamous Carcinoma [J]. Journal of International Obstetrics and Gynecology, 2025, 52(1): 32-36.
[5]	SONG Li-fang, WU Zhen-zhen, MAO Bao-hong, ZHAO Xiao-li, LIU Qing. A Case of Isolated Lymph Node Metastasis from Ovarian Cancer to the Inguinal Region [J]. Journal of International Obstetrics and Gynecology, 2025, 52(1): 37-41.
[6]	LIU Si-min, LI Hong-li, GUO Xi, HU Ya-li, YANG Yong-xiu. Late Pregnancy with Ovarian Serous Cystadenoma Pedicle Torsion: A Case Report [J]. Journal of International Obstetrics and Gynecology, 2024, 51(6): 632-635.
[7]	HUANG Mo-ya, ZHAO Ya-qian, HE Yin-fang. Progress in the Diagnosis and Treatment of Pregnancy Complicated by Krukenberg Tumor [J]. Journal of International Obstetrics and Gynecology, 2024, 51(5): 531-535.
[8]	ZHANG Jian-nan, GUO Xin, GUO Nan, NING Wen-ting, YU Hong-xin, SHANG Hai-xia. Application of Microfluidic Technology in Ovarian Cancer Disease Modeling, Drug Evaluation, and Precision Medicine [J]. Journal of International Obstetrics and Gynecology, 2024, 51(5): 560-565.
[9]	JIN Xiao-lei, XU Fei-xue. Five Cases of Diagnosis and Treatment of Ovarian Brenner Tumors [J]. Journal of International Obstetrics and Gynecology, 2024, 51(5): 578-583.
[10]	CHEN Zhi-wei, LIU Lin. A Case of Ovarian Malignant Tumor with SMARCA4 Gene Deletion [J]. Journal of International Obstetrics and Gynecology, 2024, 51(5): 584-587.
[11]	SU Hai-qi, LI Lei. Advances in Methylation Detection for Ovarian Cancer Screening and Diagnosis [J]. Journal of International Obstetrics and Gynecology, 2024, 51(4): 366-369.
[12]	ZHANG Jing-yi, LIU Dong-zhe, CHEN Xiu-hui. Research Advances of Exosomes in Angiogenesis of Ovarian Cancer [J]. Journal of International Obstetrics and Gynecology, 2024, 51(4): 370-374.
[13]	ZHANG Ting-ting, YU Ping-yuan, CHEN Xi, ZHENG Duo, YANG Yong-xiu. A Case Report of Primary Ovarian Carcinoid with Liver Metastases [J]. Journal of International Obstetrics and Gynecology, 2024, 51(4): 380-383.
[14]	JI An-xuan, ZHAO Shu-hua. Malignant Transformation of Mature Cystic Teratoma of Ovary: A Case Report [J]. Journal of International Obstetrics and Gynecology, 2024, 51(4): 384-387.
[15]	YANG Yi, LIU Hua. A Case Report of Colon Aggressive Fibromatosis Misdiagnosed as Ovarian Tumor [J]. Journal of International Obstetrics and Gynecology, 2024, 51(3): 271-273.